Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine

Next Previous
X
Search
Trial Profile

Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; MMR-varicella zoster virus vaccine (Primary) ; Measles mumps and rubella virus vaccine-(Priorix); Varicella zoster virus vaccine live
  • Indications Chickenpox; Measles; Mumps; Rubella; Varicella zoster virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 01 Feb 2022 Results published in the Acta Paediatrica
    • 12 Apr 2021 Results of ten year follow up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine published in the Vaccine
    • 15 Mar 2021 Results of a post hoc analysis assessing the possible an absolute correlate of protection for varicella after vaccination of children with one or two varicella-containing vaccine doses, using post-immunization samples published in the Vaccine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top